EN
Home/Answers/NAION and vision loss
ALLAll countries Side effects and safety

Can tirzepatide or semaglutide cause NAION or vision loss?

What we checked20 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Semaglutide (Ozempic, Wegovy) has been linked to NAION, a rare optic nerve condition that causes sudden, often painless vision loss. European regulators call it very rare, about one extra case per 10,000 person-years in type 2 diabetes studies. Canadian and Australian tirzepatide (Mounjaro, Zepbound) labels also warn of it; US and EU ones don't.

What is NAION, and how is it linked to these medicines?

NAION is a condition of the optic nerve, thought to come from poor blood flow, causing sudden, often painless vision loss that can be permanent.1

Type 2 diabetes, obesity, high blood pressure, sleep apnoea and high cholesterol all raise the risk of NAION, so the people at risk overlap with the people who take these medicines. That point comes from a September 2026 letter to doctors from Novo Nordisk, which makes semaglutide, approved by the Saudi Food and Drug Authority.1

In June 2025, the European Medicines Agency’s safety committee concluded that NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus and Wegovy), affecting up to 1 in 10,000 people.2 The EU Wegovy product information now says there is no known time window after starting when NAION may develop, and that semaglutide should be stopped if NAION is confirmed.3 The UK regulator, the MHRA, describes the link as coming from “very rare reports”.4

How big is the risk?

The EU Wegovy product information says large studies in type 2 diabetes suggest about twice the risk, or about one extra case per 10,000 person-years.3

The UK Wegovy SmPC gives the same figures but words them more cautiously, saying the studies “may” show a link.5

A 2025 study in JAMA Network Open used US health records from people with type 2 diabetes. It compared 79,699 people on semaglutide or tirzepatide with the same number on other diabetes medicines. Over 2 years, 35 (0.04%) on semaglutide or tirzepatide had NAION, against 19 (0.02%). The authors called the overall risk low.6

Novo Nordisk’s letter says placebo-controlled trials of semaglutide and liraglutide, with 96,829 people, showed no rise in NAION, and that cause and effect has not been established.1 Australian estimates reported by the Royal Australian College of General Practitioners range from 2 to 18 extra cases per 100,000 users a year.7

Does tirzepatide carry the same warning?

Tirzepatide labels differ by country, with Canadian and Australian ones mentioning NAION and the US Zepbound label and EU Mounjaro product information leaving it out.891011

Health Canada’s Zepbound and Mounjaro monographs added a warning in June 2026. They say NAION has been reported with GLP-1 medicines as a group, and that tirzepatide should be stopped if NAION is confirmed.812

Australia’s regulator, the TGA, issued a warning covering all GLP-1 medicines sold there. Australian reports included 23 for semaglutide, 10 for tirzepatide and 3 for liraglutide. Its expert committee found the evidence may support a link for semaglutide, but not for tirzepatide.7

In the JAMA Network Open study, too few people had NAION to compare the two medicines directly.6 The MHRA says it is reviewing the evidence for other GLP-1 medicines, and we found no NAION entry in the UK Mounjaro SmPC.413

What other eye changes do the labels mention?

The US Wegovy label warns that diabetic eye disease (retinopathy) can get worse in people with type 2 diabetes, especially those who already have it.14

In a 2-year trial of semaglutide in type 2 diabetes, retinopathy complications affected 3% on semaglutide and 1.8% on placebo. Among people who already had retinopathy, it was 8.2% against 5.2%. The label says a rapid improvement in blood sugar has been linked to a temporary worsening of retinopathy.14

The same label lists blurred vision as a possible sign of low blood sugar.14 The NHS advises an urgent GP appointment or NHS 111 for blurred or double vision, or for seeing flashing lights or shapes.15

What do people on GLP-1 medicines report about NAION and eyesight?

From public patient forums: 143 Reddit threads in r/Zepbound, r/WegovyWeightLoss, r/Ozempic, r/Mounjaro, r/Semaglutide and r/mounjarouk, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the label Several share first- or second-hand stories of sudden, lasting vision loss in someone on a GLP-1 medicine. The diagnosis was often unconfirmed, and replies questioned whether some were NAION. EU product information describes NAION as a sudden loss of vision.3
  • Label says otherwise Several say their eyesight or diabetic eye disease improved on treatment. On average, the US Wegovy label reports more retinopathy complications on semaglutide than on placebo in type 2 diabetes.14
  • Matches the Australian label Several say an eye specialist looked at the optic disc. Some were advised against these medicines because of a small or crowded disc, while others were cleared with closer checks. The Australian Wegovy label says a “disc at risk” carries the highest NAION risk, with or without the medicine.16

Advice people share

  • Matches the NHS Several urge getting any new vision change checked promptly rather than guessing the cause. The NHS gives the same advice for blurred or double vision and flashing lights.15
  • Matches the Australian label Many suggest asking an optometrist or eye doctor to check for a crowded disc. The Australian Wegovy label says an optometrist or ophthalmologist can assess this risk.16
  • Matches Novo Nordisk’s letter Several point out that the link is an association, because diabetes, high blood pressure and sleep apnoea are shared risk factors. Novo Nordisk says cause and effect has not been established.1
  • Matches Australia’s expert committee Several believe the signal concerns semaglutide more than tirzepatide, though others disputed this. Australia’s committee found the evidence may support a link for semaglutide but not tirzepatide.7

In your country

Labels that mention NAION link it to semaglutide or to GLP-1 medicines as a group, but which labels mention it, especially for tirzepatide, differs by country.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Mounjaro label lists NAION among post-marketing reports for GLP-1 medicines.9 The Australian Wegovy label says a “disc at risk” can be assessed by an optometrist or ophthalmologist.16 The TGA’s warning covers all GLP-1 medicines sold in Australia.7

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: Health Canada’s Zepbound and Mounjaro monographs carry a NAION warning, added in June 2026.812 The Wegovy monograph calls NAION very rare.17

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies.

Emergency number: 15 or 112

Side effects and risks in France (in French)

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 112

Side effects and risks in Germany (in German)

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We did not open an Indian label for this page, so it relies on the EU, UK, US, Canadian and Australian labels.

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: A September 2026 letter approved by the Saudi Food and Drug Authority says the Saudi Wegovy, Ozempic and Rybelsus labels will be updated with NAION.1 We did not open a Saudi tirzepatide label.

Emergency number: 997 or 911

Side effects and risks in Saudi Arabia (in Arabic)

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a UAE label for this page, so it relies on the EU, UK, US, Canadian and Australian labels.

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: We found no NAION entry in the US Wegovy, Ozempic, Zepbound or Mounjaro prescribing information.14181019 The US Wegovy label does warn about diabetic retinopathy.14

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number Sudden dizziness, weakness or change in vision is an emergency warning sign, according to the American College of Emergency Physicians.20 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if your eyesight worsens quickly or you lose part of your vision.84 Ask for an urgent appointment if you have blurred or double vision, or see flashing lights or shapes.15

Read the full picture

Related questions

Did this answer your question?

Sources

  1. Novo Nordisk. Direct healthcare professional communication: semaglutide products (Wegovy, Ozempic and Rybelsus) and NAION, approved by the Saudi Food and Drug Authority, September 2026. sfda.gov.sa
  2. European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 2-5 June 2025. ema.europa.eu
  3. EU Wegovy (semaglutide) product information, sections 4.4 and 4.8. European Medicines Agency
  4. MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. gov.uk
  5. UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC. emc
  6. Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Network Open. 2025;8(8):e2526327. jamanetwork.com
  7. RACGP newsGP. TGA issues GLP-1 RA class-wide safety update, 23 July 2026, reporting the Therapeutic Goods Administration’s safety update. racgp.org.au
  8. Health Canada. Zepbound (tirzepatide) product monograph. pdf.hres.ca
  9. Australian Mounjaro (tirzepatide) Product Information, version A14.0, October 2026. medsinfo.com.au
  10. US Zepbound (tirzepatide) prescribing information, revised August 2026. Eli Lilly
  11. EU Mounjaro (tirzepatide) product information. European Medicines Agency
  12. Health Canada. Mounjaro (tirzepatide) product monograph. Eli Lilly Canada
  13. UK Mounjaro KwikPen (tirzepatide) SmPC. emc
  14. US Wegovy (semaglutide) prescribing information, revised June 2026. Novo Nordisk
  15. NHS. Vision loss. nhs.uk
  16. Australian Wegovy (semaglutide) Product Information. medsinfo.com.au
  17. Health Canada. Wegovy (semaglutide) product monograph. pdf.hres.ca
  18. US Ozempic (semaglutide) prescribing information. Novo Nordisk
  19. US Mounjaro (tirzepatide) prescribing information. Eli Lilly
  20. MedlinePlus, US National Library of Medicine. Recognizing medical emergencies, giving the American College of Emergency Physicians’ warning signs. medlineplus.gov

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked by Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write